Avanir Pharmaceuticals (AVNR) reports mixed FQ4 results, matching loss estimates on a per share...

|About: Avanir Pharmaceuticals, Inc (AVNR)|By:, SA News Editor

Avanir Pharmaceuticals (AVNR) reports mixed FQ4 results, matching loss estimates on a per share basis but missing on revenue. Shares are trading higher after hours however, as investors appear to be focused on the company's 561% Y/Y jump in profit due to royalty payments from Abreva and Nuedexta. Shares +2.6% AH.